They presented that the TCR frequency and clonality of the peripheral CX3CR1-positive CD8+ T cell subset (which included an enriched repertoire of tumor-specific and tumor-infiltrating CD8+ T cells) was increased in tumor-bearing mice who responded to immunotherapy. This evidence concerns the gene CD8A and neoplasm.